Prospective Grant of Start-Up Exclusive License: Manual Device for Constructing Tissue Micro Arrays and Methods for Making Cryo Arrays for Use in Association With the Device, 18360 [2013-06835]
Download as PDF
<![CDATA[
srobinson on DSK4SPTVN1PROD with NOTICES
18360
Federal Register / Vol. 78, No. 58 / Tuesday, March 26, 2013 / Notices
development and use of the Licensed
Patent Rights in combination with
Licensee’s proprietary nanosphere
encapsulation technology for the
treatment, diagnosis and imaging of
cancer tumors and metastases as well as
their respective pre-cursor dysplasia
states. Licensee’s proprietary
nanosphere encapsulation technology is
understood to consist of: (1) Methods for
manipulating the outer proteins of
human papillomavirus-derived
nanoparticles to create particles targeted
to solid tumors and distant metastases;
and (2) enhancements for the delivery of
particles created by Licensee’s
proprietary technology.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before April
25, 2013 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Jennifer Wong, M.S.,
Senior Licensing and Patenting
Manager, Cancer Branch, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–4633; Facsimile:
(301) 402–0220; Email:
wongje@mail.nih.gov.
SUPPLEMENTARY INFORMATION: There is
extensive literature on the use of viral
vectors, particularly those based on the
adenovirus, to increase the potency of
anti-tumor gene therapy. However, these
approaches have had limited success
because of limited anti-tumor effects
and unacceptable toxicity. This
invention describes the use of human
papillomavirus pseudoviruses (PsV) as a
cancer diagnostic and therapeutic.
Preliminary studies showed that PsVs
bind to ovarian tumor cells while
normal tissues were not affected. PsVs
does not infect several other normal
intact tissues but continues to
selectively infect additional cancer
cells. This technology could be an
effective anti-tumor therapy because it
has shown increased infection of cancer
cells with an inability to infect normal
cells thereby reducing potential toxicity
to patients. In addition to a potential
anti-cancer therapeutic, this technology
could also be used as a diagnostic tool
in the detection of tumor masses.
Detection can be achieved through the
use of fluorescent dye coupled particles
of PsVs that have preferential binding to
tumor tissues and not normal tissues.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
VerDate Mar<15>2010
19:07 Mar 25, 2013
Jkt 229001
209 and 37 CFR Part 404.7. The
prospective exclusive license may be
granted unless within thirty (30) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR Part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: March 18, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–06837 Filed 3–25–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive License: Manual Device for
Constructing Tissue Micro Arrays and
Methods for Making Cryo Arrays for
Use in Association With the Device
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of a start-up
exclusive license to practice the
inventions embodied in U.S. Patent No.
7,854,899, (E–098–2004/0) filed
08/26/2004 and issued 12/20/2010
entitled ‘‘Template Methods and Device
for Preparing Sample Arrays’’; by Hewitt
et al. (NCI); and U.S. Patent No.
6,951,761 9 (E–064–2001/0) filed 08/30/
2002 and issued 11/04/2005
‘‘Measurements of Multiple Molecules
Using a Cryoarray’’ by Star et al.
(NIDDK) to Micatu, Inc. having a place
of business at 231 West Water Street,
Elmira, NY 14901. The patent rights in
this invention have been assigned to the
United States of America.
DATES: Only written comments and/or
application for a license that are
received by the NIH Office of
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Technology Transfer on or before April
10, 2013 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Tedd Fenn, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Email:
fennea@mail.nih.gov; Telephone: 301–
435–5031; Facsimile: 301–402–0220.
SUPPLEMENTARY INFORMATION: The
prospective worldwide exclusive
license will be royalty bearing and will
comply with the terms and conditions
of 35 U.S.C. 209 and 37 CFR 404.7. The
prospective exclusive license may be
granted unless, within fifteen (15) days
from the date of this published Notice,
NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
The patents relate to a device for
tissue microarray construction having a
block of embedding medium, a platform
configured to retain the block, a
templates secured to the platform and
aligned to guide needles into the
embedding block; and methods of
making a block containing liquid
biological samples that can be frozen
and sectioned to make tissue
microarray.
The field of use may be limited to the
field of devices for construction of
tissue microarrays.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: March 18, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
& Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–06835 Filed 3–25–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2013 Funding
Opportunity
Substance Abuse and Mental
Health Services Administration, HHS.
AGENCY:
E:\FR\FM\26MRN1.SGM
26MRN1
]]>Agencies
[Federal Register Volume 78, Number 58 (Tuesday, March 26, 2013)]
[Notices]
[Page 18360]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-06835]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Exclusive License: Manual Device
for Constructing Tissue Micro Arrays and Methods for Making Cryo Arrays
for Use in Association With the Device
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
a start-up exclusive license to practice the inventions embodied in
U.S. Patent No. 7,854,899, (E-098-2004/0) filed 08/26/2004 and issued
12/20/2010 entitled ``Template Methods and Device for Preparing Sample
Arrays''; by Hewitt et al. (NCI); and U.S. Patent No. 6,951,761 9 (E-
064-2001/0) filed 08/30/2002 and issued 11/04/2005 ``Measurements of
Multiple Molecules Using a Cryoarray'' by Star et al. (NIDDK) to
Micatu, Inc. having a place of business at 231 West Water Street,
Elmira, NY 14901. The patent rights in this invention have been
assigned to the United States of America.
DATES: Only written comments and/or application for a license that are
received by the NIH Office of Technology Transfer on or before April
10, 2013 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Tedd Fenn, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; Email: fennea@mail.nih.gov; Telephone: 301-
435-5031; Facsimile: 301-402-0220.
SUPPLEMENTARY INFORMATION: The prospective worldwide exclusive license
will be royalty bearing and will comply with the terms and conditions
of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license
may be granted unless, within fifteen (15) days from the date of this
published Notice, NIH receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The patents relate to a device for tissue microarray construction
having a block of embedding medium, a platform configured to retain the
block, a templates secured to the platform and aligned to guide needles
into the embedding block; and methods of making a block containing
liquid biological samples that can be frozen and sectioned to make
tissue microarray.
The field of use may be limited to the field of devices for
construction of tissue microarrays.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: March 18, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-06835 Filed 3-25-13; 8:45 am]
BILLING CODE 4140-01-P
